Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, Kaifeng, 475004, Henan, China.
Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
J Hematol Oncol. 2023 Aug 3;16(1):90. doi: 10.1186/s13045-023-01488-4.
Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20 NHL cells in clinical trials. Mosunetuzumab, epcoritamab and glofitamab have been approved recently for B-cell NHL therapy. In this study, we summarized several latest reports on CD20 × CD3 bsAbs for the therapy of B-cell NHL from the ASCO 2023 annual meeting (ASCO2023).
多种双特异性抗体（bsAbs）已被批准用于癌症免疫治疗。几项 CD20×CD3 bsAbs 在临床试验中通过招募 T 细胞来靶向 CD20 NHL 细胞，显示出显著的抗 B 细胞非霍奇金淋巴瘤（NHL）活性。Mosunetuzumab、epcoritamab 和 glofitamab 最近已被批准用于 B 细胞 NHL 治疗。在这项研究中，我们总结了 ASCO2023 年年会（ASCO2023）上关于 CD20×CD3 bsAbs 治疗 B 细胞 NHL 的几项最新报告。
